The Comparison of Insulin Sensitivity in Non-diabetic Hemodialysis Patients Treated with and without Recombinant Human Erythropoietin

Abstract

Background: Patients with end-stage renal disease (ESRD) are known to have insulin resistance. Treatment with EPO is associated with improvement in insulin sensitivity in uremic patients. The aim of this study was to compare insulin sensitivity and pancreatic B cell function in adult non-diabetic uremic hemodialysis patients treated with or without rHuEPO. Subjects and Methods: Three groups of subjects were included to the study: hemodialysis patients treated with rHuEPO [EPO(+) group] or without rHuEPO [EPO(-) group], and healthy controls. Anthropometrical parameters, lipid levels, fasting glucose and insulin levels were measured in all subjects. Homeostasis Model Assessment (HOMA) was used to compare insulin sensitivity. ANOVA, independent t-test, and Pearson correlation were used for statistical analysis. Results: Mean insulin level of control group (20.04 ± 7.2 pmol/l) was significantly lower than EPO(+) group (p < 0.04) and EPO(-) group (p < 0.0001). HOMA-(%B) levels in the EPO(+) group were significantly lower than in the EPO(-) group (106 ± 42, 140 ± 63 respectively, p < 0.02). HOMA-(%B) levels in the control group (66 ± 17) were significantly lower than in the EPO(+) and EPO(-) group (p < 0.005 and p < 0.0001 respectively). HOMA-(%S) levels in the EPO(+) groups was significantly higher than in the EPO(-) group (91 ± 40, 56 ± 26, respectively; p < 0.01). HOMA-(%S) levels of control group (125 ± 24) was significantly higher than EPO(+) and EPO(-) groups (p < 0.02, p < 0.0001 respectively). We found a positive correlation between duration of erythropoietin treatment and insulin sensitivity (r = 0.484, p < 0.002). Conclusions: Firstly, patients treated with EPO are insulin sensitive compared to patients not treated with EPO. Secondly, duration of erythropoietin treatment is positively correlated with insulin sensitivity in hemodialysis patients.

Key words

EPO - Hemodialysis - HOMA-(%B) - HOMA-(%S) - Insulin - Uremia

References

• 1 Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y. Insulin resistance as an independent predictor of cardiovascular mortality inpatients with end-stage renal disease.  J Am Soc Nephrol. 2002;  13 1894-1900
• 2 Hager S R. Insulin resistance of uremia.  Am J Kidney Dis. 1989;  14 272-276
• 3 Spaia S, Pangalos M, Askepidis N, Pazarloglou M, Mavropoulou E, Theodoridis S, Dimitrakopoulos K, Milionis A, Vayonas G. Effect of short-term rHuEPO treatment on insulin resistance in hemodialysis patients.  Nephron. 2000;  84 320-325
• 4 Rasic-Milutinovic Z, Perunicic-Pekovic G, Pljesa S. Clinical significance and pathogenic mechanisms of insulin resistance in chronic renal insufficiency (part II): pathogenic factors of insulin resistance in chronic renal insufficiency.  Med Pregl. 2000;  53 159-163
• 5 Oshida Y, Sato Y, Shiraishi S, Sakamoto N. Studies on glucose intolerance in chronic renal failure: Estimation of insulin sensitivity before and after initiation of hemodialysis.  Clin Nephrol. 1987;  28 35-38
• 6 Matthews D R, Hosker J P, Rudenski A S, Burnett M A, Darling P. et al . Homeostasis model assessment: insulin resitance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 7 Perez-Martin A, Raynaud E, Hentgen C, Bringer J, Mercier J, Brun J F. Simplified measurement of insulin sensitivity with the minimal model procedure in type 2 diabetic patients without measurement of insulinemia.  Horm Metab Res. 2002;  34 102-106
• 8 Mak R H. 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients.  Kidney Int. 1992;  41 1048-1054
• 9 Borissova A M, Djambazova A, Todorov K, Dakovska L, Tankova T, Kirilov G. Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on hemodialysis.  Nephrol Dial Transplant. 1993;  8 93-95
• 10 Chagnac A, Korzets A, Zevin D, Korzets A, Hirsh J, Gafter U, Levi J. Effect of erythropoietin on glucose tolerance in hemodialysis patients.  Clin Nephrol. 1994;  42 398-400
• 11 Mak R H. Metabolic effects of erythropoietin in patients on peritoneal dialysis.  Pediatr Nephrol. 1998;  12 660-665
• 12 Stefanovic V, Nesic V, Stojimirovic B. Treatment of insulin resistance in uremia.  Int J Artif Organs. 2003;  26 100-104
• 13 NKF K/DOQI Clinical practice guidelines 2000 The National Kidney Foundation. www.kidney.org/professionals/doqi/guidelines. 
• 14 Shoji T, Emoto M, Nishizawa Y. HOMA index to assess insulin resistance in renal failure patients.  Nephron. 2001;  89 348-349
• 15 Beck-Nielsen H. Insulin resistance: Organ manifestations and cellular mechanisms.  Ugeskr Laeger. 2002;  164 2130-2135
• 16 Mak R H. Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia.  J Pediatr. 1996;  129 97-104
• 17 Wu Z, Bao X. Effects of benazepril on insulin resistance and glucose tolerance in uremia.  Clin Nephrol. 1998;  50 108-112
• 18 Eschback J W, Kelly M R, Haley N R, Abels I, Adamson J W. Correction of anemia in progressive renal failure with recombinant human erythropoietin.  N Engl J Med. 1989;  321 158-163
• 19 Barrany P, Peterson E, Ahberg M, Hultman E, Bergstrom J. Nutritional assessment in anemic hemodialysis patients treated with human recombinant erythropoietin.  Clin Nephrol. 1991;  35 270-279
• 20 Mak R H, Turner C, Haycock G B, Chantler C. Secondary hyperthyroidism and glucose intolerance in children with uremia.  Kidney Int. 1983;  16 (Suppl 24) 122